RecruitingPhase 4NCT05428826

Early Discontinuation of Steroid Treatment in Negative FDG-PET/CT Patients With Idiopathic Retroperitoneal Fibrosis

Studying IgG4-related retroperitoneal fibrosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Assistance Publique - Hôpitaux de Paris
Principal Investigator: Aline DECHANET
Assistance Publique - Hôpitaux de Paris (AP-HP)
Intervention: Prednisone(drug)
Enrollment: 41 target
Eligibility: 18 years · All sexes
Timeline: 2022 – 2028

Study locations (15)

Médecine Interne, Agen, France, France
Médecine interne, Brest, France, France
Médecine interne et maladies infectieuses - GH Sud Haut Lévêque, Bordeaux, France
Médecine interne - Ambroise Paré, Boulogne-Billancourt, France
Médecine interne - Henri-Mondor, Créteil, France
Médecine interne et immunologie clinique - Dijon, Dijon, France
Médecine interne - Lille, Lille, France
Médecine Interne - La Timone, Marseille, France
Médecine interne - Saint Antoine, Paris, France
Médecine Interne, Vascularites et Myosites - La Pitié Salpêtrière, Paris, France
Médecine interne - Cochin, Paris, France
Médecine vasculaire - HEGP, Paris, France
Médecine Interne - Bichat, Paris, France
Néphrologie - Bichat, Paris, France
Médecine interne - Delafontaine, Saint-Denis, France

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05428826 on ClinicalTrials.gov

Other trials for IgG4-related retroperitoneal fibrosis

Additional recruiting or active studies for the same condition.

See all trials for IgG4-related retroperitoneal fibrosis →

← Back to all trials